Romina Hamzehpour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Romina Hamzehpour has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Angela Hamidia
Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
3 shared publications - Sussan Moudi
Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
3 shared publications - Ali Bijani
Social Determinant of Health Research Center, Babol University of Medical Sciences, Babol, Iran
2 shared publications - Farzan Kheirkhah
Department of Psychiatry, School of Medicine, Health Research Institute Babol University of Medical Sciences Babol Iran
2 shared publications - Hoda Shirafkan
Social Determinants of Health Research Center, Health Research Institute Babol University of Medical Sciences Babol Iran
2 shared publications - Mohammad Barary
Student Research Committee, Department of Pharmacology School of Medicine, Shahid Beheshti University of Medical Sciences Tehran Iran
2 shared publications
Latest Publications
- Open Access
- 20 August 2025
- Published by Wiley in Chronic Diseases and Translational Medicine
- Vol. 11 (4) , 320-321
Commentary on “HDL‐C/LDL‐C Ratio and All‐Cause Mortality in Populations at High CVD Risk: A Prospective Observational Cohort Study”
- 20 August 2025
- Published by Wiley in Chronic Diseases and Translational Medicine
- Vol. 11 (4) , 320-321
Open AccessCommentary on “HDL‐C/LDL‐C Ratio and All‐Cause Mortality in Populations at High CVD Risk: A Prospective Observational Cohort Study”
- 30 June 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (1) , 143-152
Efficacy of donepezil versus donepezil and trazodone in combination cognitive dysfunction in patients with dementia: a randomized controlled trial
Cognitive disorders, including dementia, are a major challenge for public health systems worldwide, particularly among elderly individuals. The present study aimed to compare the effectiveness of donepezil alone versus donepezil combined with trazodone in improving cognitive dysfunction in dementia. In this randomized controlled trial, a total of 60 patients with dementia according to the DSM-V referred to the Babol University of Medical Sciences Center for Elderly individuals were randomly assigned to receive either donepezil 5–10 mg daily (Group A) or donepezil 5–10 mg plus trazodone 25–100 mg daily (Group B) for 6 months. Cognitive status was assessed at baseline, 3 months, and 6 months using the Mini-Mental State Examination (MMSE) and the Addenbrook’s scale. All adverse drug reactions were compared. Both groups showed significant improvement from baseline in MMSE and Adent Brook scores over 6 months (p < 0.001). No significant differences in clinical efficacy or side effect reactions were observed between the groups (p > 0.05). Tiredness was a more common side effect of the combination treatment. Adding trazodone to donepezil showed no cognitive benefits over donepezil alone. While trazodone may help with sleep and behavioral issues, it does not improve cognition in dementia patients. Larger studies with longer follow-ups and varied trazodone doses across dementia subtypes are needed. Iranian Registry for Clinical Trial (ID: IRCT20190317043079N1) registration date: 04/10/2019.
- 30 June 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (1) , 143-152
Efficacy of donepezil versus donepezil and trazodone in combination cognitive dysfunction in patients with dementia: a randomized controlled trial
Cognitive disorders, including dementia, are a major challenge for public health systems worldwide, particularly among elderly individuals. The present study aimed to compare the effectiveness of donepezil alone versus donepezil combined with trazodone in improving cognitive dysfunction in dementia. In this randomized controlled trial, a total of 60 patients with dementia according to the DSM-V referred to the Babol University of Medical Sciences Center for Elderly individuals were randomly assigned to receive either donepezil 5–10 mg daily (Group A) or donepezil 5–10 mg plus trazodone 25–100 mg daily (Group B) for 6 months. Cognitive status was assessed at baseline, 3 months, and 6 months using the Mini-Mental State Examination (MMSE) and the Addenbrook’s scale. All adverse drug reactions were compared. Both groups showed significant improvement from baseline in MMSE and Adent Brook scores over 6 months (p < 0.001). No significant differences in clinical efficacy or side effect reactions were observed between the groups (p > 0.05). Tiredness was a more common side effect of the combination treatment. Adding trazodone to donepezil showed no cognitive benefits over donepezil alone. While trazodone may help with sleep and behavioral issues, it does not improve cognition in dementia patients. Larger studies with longer follow-ups and varied trazodone doses across dementia subtypes are needed. Iranian Registry for Clinical Trial (ID: IRCT20190317043079N1) registration date: 04/10/2019.
- Open Access
- 6 April 2025
- Published by Brieflands in Iranian Journal of Psychiatry and Behavioral Sciences
- Vol. 19 (2)
Prevalence of Non-suicidal Self-Injury in the General Population in Iran: A Systematic Review and Meta-Analysis
Context: Non-suicidal self-injury (NSSI) is an intentional behavior without suicidal intent, recently recognized as an independent diagnostic entity in the diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Various studies indicate that NSSI is prevalent worldwide, but there are no reports on its prevalence among the Iranian population. Evidence Acquisition: A systematic review of the literature was conducted using databases such as Scopus, PubMed/Medline, Web of Science, IMBIS, Google Scholar, Cochrane, and PsycInfo. Domestic databases, including Iran Medex, Mogiran, and SID, were also utilized. All available data until the end of June 2024 were reviewed. Data extraction was performed by two researchers, and study quality was assessed using the Newcastle-Ottawa Scale (NOS). Studies on NSSI in the general population of Iran that reported prevalence rates and accurate sample sizes were included. The heterogeneity of the studies was evaluated using the Cochran test and I2 statistics. Additionally, a meta-regression analysis was conducted based on the year of study. Results: A total of 2,180 articles were reviewed, with 17 articles ultimately selected and included in the study. The random-effects model estimated the pooled prevalence of NSSI in the general population at 16.51% (95% CI, 13.59 - 19.43). The prevalence of NSSI in women and men was 19.27% (95% CI, 13.31 - 25.24) and 14.74% (95% CI, 10.53 - 18.94), respectively. A correlation was found between the number of years since the study was conducted and the prevalence of NSSI (Reg Coef = 0.01, 95% CI: 0.003 to 0.020, P = 0.011); newer studies reported higher prevalence rates. Conclusions: The present study revealed a high prevalence of NSSI in the general population, particularly in certain provinces and among women, indicating the need for specific prevention and treatment programs.
- 6 April 2025
- Published by Brieflands in Iranian Journal of Psychiatry and Behavioral Sciences
- Vol. 19 (2)
Open AccessPrevalence of Non-suicidal Self-Injury in the General Population in Iran: A Systematic Review and Meta-Analysis
Context: Non-suicidal self-injury (NSSI) is an intentional behavior without suicidal intent, recently recognized as an independent diagnostic entity in the diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Various studies indicate that NSSI is prevalent worldwide, but there are no reports on its prevalence among the Iranian population. Evidence Acquisition: A systematic review of the literature was conducted using databases such as Scopus, PubMed/Medline, Web of Science, IMBIS, Google Scholar, Cochrane, and PsycInfo. Domestic databases, including Iran Medex, Mogiran, and SID, were also utilized. All available data until the end of June 2024 were reviewed. Data extraction was performed by two researchers, and study quality was assessed using the Newcastle-Ottawa Scale (NOS). Studies on NSSI in the general population of Iran that reported prevalence rates and accurate sample sizes were included. The heterogeneity of the studies was evaluated using the Cochran test and I2 statistics. Additionally, a meta-regression analysis was conducted based on the year of study. Results: A total of 2,180 articles were reviewed, with 17 articles ultimately selected and included in the study. The random-effects model estimated the pooled prevalence of NSSI in the general population at 16.51% (95% CI, 13.59 - 19.43). The prevalence of NSSI in women and men was 19.27% (95% CI, 13.31 - 25.24) and 14.74% (95% CI, 10.53 - 18.94), respectively. A correlation was found between the number of years since the study was conducted and the prevalence of NSSI (Reg Coef = 0.01, 95% CI: 0.003 to 0.020, P = 0.011); newer studies reported higher prevalence rates. Conclusions: The present study revealed a high prevalence of NSSI in the general population, particularly in certain provinces and among women, indicating the need for specific prevention and treatment programs.
- Open Access
- 13 March 2025
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 33 (156) , 1-10
The Comparison of the Efficacy of Agomelatine and Sertraline Medications in the Treatment of Depressive Symptoms in Patients with Heart Failure: A Randomized Double-Blind Clinical Trial
Objectives & Aims: Depression impacts 20% of heart failure (HF) patients, doubling their mortality risk and tripling non-compliance with treatment. This study compares the effectiveness of Agomelatine and Sertraline in treating depression in these patients. Methods: This double-blind, randomized clinical trial study was conducted on 58 patients referred to Babol ...
- 13 March 2025
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 33 (156) , 1-10
Open AccessThe Comparison of the Efficacy of Agomelatine and Sertraline Medications in the Treatment of Depressive Symptoms in Patients with Heart Failure: A Randomized Double-Blind Clinical Trial
Objectives & Aims: Depression impacts 20% of heart failure (HF) patients, doubling their mortality risk and tripling non-compliance with treatment. This study compares the effectiveness of Agomelatine and Sertraline in treating depression in these patients. Methods: This double-blind, randomized clinical trial study was conducted on 58 patients referred to Babol ...
- 10 January 2025
- Published by Elsevier in Journal of Pediatric and Adolescent Gynecology
- Vol. 38 (3) , 320-327
Improving Pubertal Health Education for Adolescent Girls Through a Gamified Learning Approach
- 10 January 2025
- Published by Elsevier in Journal of Pediatric and Adolescent Gynecology
- Vol. 38 (3) , 320-327
Improving Pubertal Health Education for Adolescent Girls Through a Gamified Learning Approach
- Open Access
- 29 September 2024
- Published by Springer Nature in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
- Vol. 60 (1) , 1-11
Investigating alexithymia, empathy, and resilience in medical students during pandemic era: a cross-sectional study in northern Iran
Background and aim: Alexithymia is defined as emotional response inhibition. As well, empathy refers to the ability to put oneself in someone’s position and resilience is the capacity to recover from a series of negative emotional experiences. Considering the psychological distress induced by the coronavirus disease 2019 (COVID-19) pandemic together with academic stress and the role of empathy in physician–patient relationships, the present study was to investigate alexithymia, empathy, and resilience in Iranian medical interns and residents. Materials and methods: This cross-sectional study was fulfilled in northern Iran in 2021–2022. In total, 394 medical interns and residents were initially recruited for this purpose. Then, an online sociodemographic survey form (SDSF), the Jefferson Scale of Empathy (JSE), the Toronto Alexithymia Scale (TAS-20), and the Connor–Davidson Resilience Scale (CD-RISC) were completed. The data analysis was performed using the IBM SPSS Statistics (ver.26) software in regard to the p < 0.05 significance level. Results: The mean age of the study participants was 28.8 ± 5.00. As well, 38.1% of these individuals were male, 62.2% of the cases were single, and 54.6% of them were medical interns. The mean value of empathy, resilience and alexithymia was 89.90 ± 14.00, 49.75 ± 10.56, and 46.40 ± 16.40, respectively. No significant relationship was found between empathy and educational level (p = 0.532). As well, medical interns empathy and resilience than residents (p = 0.000 & p = 0.000, respectively). Besides, male participants had more empathy and resilience (p = 0.000 & p = 0.007). Conclusion: Low empathy and resilience in medical interns and residents, especially in women who make up the majority of them, can be a warning for health care in Iran.
- 29 September 2024
- Published by Springer Nature in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
- Vol. 60 (1) , 1-11
Open AccessInvestigating alexithymia, empathy, and resilience in medical students during pandemic era: a cross-sectional study in northern Iran
Background and aim: Alexithymia is defined as emotional response inhibition. As well, empathy refers to the ability to put oneself in someone’s position and resilience is the capacity to recover from a series of negative emotional experiences. Considering the psychological distress induced by the coronavirus disease 2019 (COVID-19) pandemic together with academic stress and the role of empathy in physician–patient relationships, the present study was to investigate alexithymia, empathy, and resilience in Iranian medical interns and residents. Materials and methods: This cross-sectional study was fulfilled in northern Iran in 2021–2022. In total, 394 medical interns and residents were initially recruited for this purpose. Then, an online sociodemographic survey form (SDSF), the Jefferson Scale of Empathy (JSE), the Toronto Alexithymia Scale (TAS-20), and the Connor–Davidson Resilience Scale (CD-RISC) were completed. The data analysis was performed using the IBM SPSS Statistics (ver.26) software in regard to the p < 0.05 significance level. Results: The mean age of the study participants was 28.8 ± 5.00. As well, 38.1% of these individuals were male, 62.2% of the cases were single, and 54.6% of them were medical interns. The mean value of empathy, resilience and alexithymia was 89.90 ± 14.00, 49.75 ± 10.56, and 46.40 ± 16.40, respectively. No significant relationship was found between empathy and educational level (p = 0.532). As well, medical interns empathy and resilience than residents (p = 0.000 & p = 0.000, respectively). Besides, male participants had more empathy and resilience (p = 0.000 & p = 0.007). Conclusion: Low empathy and resilience in medical interns and residents, especially in women who make up the majority of them, can be a warning for health care in Iran.
- Open Access
- 17 September 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (11) , 6546-6554
The comparison of efficacy of Escitalopram and Bupropion in treatment of depression symptoms in patients with heart failure: randomized clinical trial
Objective: This study aims to compare the effects of two medicines, Escitalopram and Bupropion, on HF patients who have depression symptoms. Methods: This double-blind randomized clinical trial study was conducted on HF patients with depression symptoms at the Heart Failure Clinics affiliated with Babol University of Medical Sciences. In this study, 80 participants were examined for depression based on the Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HDRS). They were randomly allocated into two groups of 40 participants treated with Bupropion 75 mg and Escitalopram 5 mg. Following the intervention, the individuals were assessed in terms of their depression score at 4, 8, and 12-week intervals. Finally, the data were analyzed using SPSS version 22.0. Results: In the examination of Beck and Hamilton scores in the two research groups during different follow-ups, a significant decrease was found over time (P0.05 in all cases). Comparing the side effects between the two intervention groups, the orgasm disorder (P=0.018) and sexual dysfunction (P<0.001) were reported significantly more in the Escitalopram group than in the Bupropion group. Conclusions: The findings of this study showed that Escitalopram has the same efficacy as Bupropion in the treatment of depression symptoms in HF patients.
- 17 September 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (11) , 6546-6554
Open AccessThe comparison of efficacy of Escitalopram and Bupropion in treatment of depression symptoms in patients with heart failure: randomized clinical trial
Objective: This study aims to compare the effects of two medicines, Escitalopram and Bupropion, on HF patients who have depression symptoms. Methods: This double-blind randomized clinical trial study was conducted on HF patients with depression symptoms at the Heart Failure Clinics affiliated with Babol University of Medical Sciences. In this study, 80 participants were examined for depression based on the Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HDRS). They were randomly allocated into two groups of 40 participants treated with Bupropion 75 mg and Escitalopram 5 mg. Following the intervention, the individuals were assessed in terms of their depression score at 4, 8, and 12-week intervals. Finally, the data were analyzed using SPSS version 22.0. Results: In the examination of Beck and Hamilton scores in the two research groups during different follow-ups, a significant decrease was found over time (P0.05 in all cases). Comparing the side effects between the two intervention groups, the orgasm disorder (P=0.018) and sexual dysfunction (P<0.001) were reported significantly more in the Escitalopram group than in the Bupropion group. Conclusions: The findings of this study showed that Escitalopram has the same efficacy as Bupropion in the treatment of depression symptoms in HF patients.
- Open Access
- 15 October 2022
- Published by Scientific Scholar in Global Journal of Medical, Pharmaceutical, and Biomedical Update
- Vol. 17 (20) , 20
Comparative Effect of Escitalopram and Citalopram on Depressive Symptoms of Patients with Schizophrenia: A Double-Blind Randomized Controlled Trial
Objectives: Given the importance of the management of depression in patients with schizophrenia, this research was carried out to compare the therapeutic effects of escitalopram and citalopram on depressive symptoms of these patients. Material and Methods: This double-blind randomized controlled trial was conducted on 60 patients diagnosed with schizophrenia. The patients who had depression based on the Calgary Depression Scale for Schizophrenia (CDSS) were included in the study. The first group received 10–40 mg/day of citalopram, and the second group received 5–20 mg/day of escitalopram. The patients were treated for 8 weeks. Any reduction in depressive symptoms based on the CDSS measure was considered the primary outcome of the research. Results: Although the two groups had no significant difference in CDSS score at the initial assessment (P = 0.86), after 8 weeks, the depressive symptoms decreased and a significant difference was observed between the two groups (P = 0.03). The two groups had no significant difference in drug side effects, except for anorexia (P = 0.03). Conclusion: Depressive symptoms decreased significantly after 8 weeks of treatment with both citalopram and escitalopram; however, these symptoms had more reduction in patients taking escitalopram than the individuals receiving citalopram.
- 15 October 2022
- Published by Scientific Scholar in Global Journal of Medical, Pharmaceutical, and Biomedical Update
- Vol. 17 (20) , 20
Open AccessComparative Effect of Escitalopram and Citalopram on Depressive Symptoms of Patients with Schizophrenia: A Double-Blind Randomized Controlled Trial
Objectives: Given the importance of the management of depression in patients with schizophrenia, this research was carried out to compare the therapeutic effects of escitalopram and citalopram on depressive symptoms of these patients. Material and Methods: This double-blind randomized controlled trial was conducted on 60 patients diagnosed with schizophrenia. The patients who had depression based on the Calgary Depression Scale for Schizophrenia (CDSS) were included in the study. The first group received 10–40 mg/day of citalopram, and the second group received 5–20 mg/day of escitalopram. The patients were treated for 8 weeks. Any reduction in depressive symptoms based on the CDSS measure was considered the primary outcome of the research. Results: Although the two groups had no significant difference in CDSS score at the initial assessment (P = 0.86), after 8 weeks, the depressive symptoms decreased and a significant difference was observed between the two groups (P = 0.03). The two groups had no significant difference in drug side effects, except for anorexia (P = 0.03). Conclusion: Depressive symptoms decreased significantly after 8 weeks of treatment with both citalopram and escitalopram; however, these symptoms had more reduction in patients taking escitalopram than the individuals receiving citalopram.
- Open Access
- 5 July 2022
- Published by Brieflands in Shiraz E-Medical Journal
- Vol. 23 (8)
Psychiatric Consultation to Hospitalized Patients: Current Status and Psychiatric Diagnoses
Background: The benefits of addressing behavioral health issues in inpatients have been well documented. However, these problems are not frequently recognized by physicians during the hospitalization of patients in general hospitals. Objectives: This study described the current status and medical diagnoses made in psychiatric consultations to inpatients admitted to general hospitals affiliated to Babol University of Medical Sciences, North of Iran. Methods: This cross-sectional observational research was carried out at Babol University of Medical Sciences from 2019 to 2020. All psychiatric consultations for patients hospitalized in different departments of two general hospitals affiliated to this university for 6 months were included. The mental disorders diagnosed for patients were recorded by a psychiatrist according to the diagnostic and statistical manual of mental disorders (DSM-5) criteria. Results: A total of 266 patients with a mean age of 51.21 ± 16.95 years were examined. Most of the consults were requested by the departments of cardiology (39.5%) and neurology (16.2%). According to the psychiatric visits, 32.3%, 51.1%, and 15.4% of the patients had no, one, and two concomitant psychiatric disorders, respectively. Mental disorders were found to have a significant association with gender (P < 0.001), admission department (P < 0.001), comorbid malignancies (P = 0.011), cardiovascular disorders (P < 0.001), need for surgical intervention (P = 0.018), a history of substance use (P = 0.001), and reasons for consult request (P < 0.001). Conclusions: Mental disorders, especially mood and anxiety disorders, were identified in approximately 70% of consultations. Therefore, requesting a timely psychiatric consultation can lead to better managing hospitalized patients.
- 5 July 2022
- Published by Brieflands in Shiraz E-Medical Journal
- Vol. 23 (8)
Open AccessPsychiatric Consultation to Hospitalized Patients: Current Status and Psychiatric Diagnoses
Background: The benefits of addressing behavioral health issues in inpatients have been well documented. However, these problems are not frequently recognized by physicians during the hospitalization of patients in general hospitals. Objectives: This study described the current status and medical diagnoses made in psychiatric consultations to inpatients admitted to general hospitals affiliated to Babol University of Medical Sciences, North of Iran. Methods: This cross-sectional observational research was carried out at Babol University of Medical Sciences from 2019 to 2020. All psychiatric consultations for patients hospitalized in different departments of two general hospitals affiliated to this university for 6 months were included. The mental disorders diagnosed for patients were recorded by a psychiatrist according to the diagnostic and statistical manual of mental disorders (DSM-5) criteria. Results: A total of 266 patients with a mean age of 51.21 ± 16.95 years were examined. Most of the consults were requested by the departments of cardiology (39.5%) and neurology (16.2%). According to the psychiatric visits, 32.3%, 51.1%, and 15.4% of the patients had no, one, and two concomitant psychiatric disorders, respectively. Mental disorders were found to have a significant association with gender (P < 0.001), admission department (P < 0.001), comorbid malignancies (P = 0.011), cardiovascular disorders (P < 0.001), need for surgical intervention (P = 0.018), a history of substance use (P = 0.001), and reasons for consult request (P < 0.001). Conclusions: Mental disorders, especially mood and anxiety disorders, were identified in approximately 70% of consultations. Therefore, requesting a timely psychiatric consultation can lead to better managing hospitalized patients.